Vamil Divan
Stock Analyst at Guggenheim
(4.67)
# 197
Out of 4,996 analysts
236
Total ratings
65.27%
Success rate
18.37%
Average return
Main Sectors:
Stocks Rated by Vamil Divan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Upgrades: Buy | $167 → $206 | $179.71 | +14.63% | 17 | Sep 23, 2025 | |
| SVRA Savara | Maintains: Buy | $8 → $11 | $3.52 | +212.50% | 2 | Sep 9, 2025 | |
| VALN Valneva SE | Maintains: Buy | $14 → $13 | $9.71 | +33.88% | 2 | Sep 8, 2025 | |
| ANIP ANI Pharmaceuticals | Maintains: Buy | $86 → $114 | $93.05 | +22.51% | 12 | Sep 8, 2025 | |
| INSM Insmed | Maintains: Buy | $125 → $172 | $137.03 | +25.52% | 7 | Sep 8, 2025 | |
| ASMB Assembly Biosciences | Maintains: Buy | $31 → $39 | $24.73 | +57.70% | 2 | Sep 8, 2025 | |
| ABBV AbbVie | Maintains: Buy | $216 → $227 | $220.61 | +2.90% | 27 | Aug 1, 2025 | |
| PROK ProKidney | Maintains: Buy | $6 → $7 | $2.49 | +181.12% | 2 | Jul 14, 2025 | |
| JBIO Jade Biosciences | Upgrades: Buy | $14 | $8.48 | +65.09% | 1 | Jun 16, 2025 | |
| AMGN Amgen | Assumes: Neutral | $288 | $272.98 | +5.50% | 1 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $4.02 | +1,392.54% | 1 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $115 | $78.56 | +46.38% | 14 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $47 | $25.30 | +85.77% | 8 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.73 | +266.30% | 3 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $23.76 | - | 22 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $59 → $61 | $28.20 | +116.31% | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $16.05 | - | 5 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $1.81 | +1,336.46% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $9 | $1.08 | +737.21% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.70 | - | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $19 | $21.05 | -9.74% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $98 | $142.00 | -30.99% | 8 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $34 | $27.89 | +21.91% | 13 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $2.36 | +323.73% | 3 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $49 | $116.76 | -58.03% | 3 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $356 | $724.54 | -50.87% | 17 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $8.18 | -26.65% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $144 → $154 | $15.00 | +926.67% | 9 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $5.99 | +150.63% | 5 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $33.78 | - | 6 | Dec 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $18.34 | - | 13 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 | $7.39 | +102.98% | 4 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $61 | $44.12 | +38.26% | 8 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $103 | $2.65 | +3,786.79% | 3 | Jan 17, 2018 |
Johnson & Johnson
Sep 23, 2025
Upgrades: Buy
Price Target: $167 → $206
Current: $179.71
Upside: +14.63%
Savara
Sep 9, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $3.52
Upside: +212.50%
Valneva SE
Sep 8, 2025
Maintains: Buy
Price Target: $14 → $13
Current: $9.71
Upside: +33.88%
ANI Pharmaceuticals
Sep 8, 2025
Maintains: Buy
Price Target: $86 → $114
Current: $93.05
Upside: +22.51%
Insmed
Sep 8, 2025
Maintains: Buy
Price Target: $125 → $172
Current: $137.03
Upside: +25.52%
Assembly Biosciences
Sep 8, 2025
Maintains: Buy
Price Target: $31 → $39
Current: $24.73
Upside: +57.70%
AbbVie
Aug 1, 2025
Maintains: Buy
Price Target: $216 → $227
Current: $220.61
Upside: +2.90%
ProKidney
Jul 14, 2025
Maintains: Buy
Price Target: $6 → $7
Current: $2.49
Upside: +181.12%
Jade Biosciences
Jun 16, 2025
Upgrades: Buy
Price Target: $14
Current: $8.48
Upside: +65.09%
Amgen
May 20, 2025
Assumes: Neutral
Price Target: $288
Current: $272.98
Upside: +5.50%
Apr 21, 2025
Initiates: Buy
Price Target: $60
Current: $4.02
Upside: +1,392.54%
Apr 17, 2025
Reiterates: Buy
Price Target: $115
Current: $78.56
Upside: +46.38%
Apr 14, 2025
Reiterates: Buy
Price Target: $47
Current: $25.30
Upside: +85.77%
Mar 20, 2025
Reiterates: Buy
Price Target: $10
Current: $2.73
Upside: +266.30%
Mar 18, 2025
Reiterates: Buy
Price Target: n/a
Current: $23.76
Upside: -
Feb 27, 2025
Maintains: Buy
Price Target: $59 → $61
Current: $28.20
Upside: +116.31%
Jan 17, 2025
Reiterates: Neutral
Price Target: n/a
Current: $16.05
Upside: -
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $1.81
Upside: +1,336.46%
Apr 3, 2023
Maintains: Buy
Price Target: $8 → $9
Current: $1.08
Upside: +737.21%
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $2.70
Upside: -
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $21.05
Upside: -9.74%
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $142.00
Upside: -30.99%
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $27.89
Upside: +21.91%
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $2.36
Upside: +323.73%
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $116.76
Upside: -58.03%
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $724.54
Upside: -50.87%
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $8.18
Upside: -26.65%
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $15.00
Upside: +926.67%
May 6, 2021
Upgrades: Buy
Price Target: $15
Current: $5.99
Upside: +150.63%
Dec 13, 2019
Downgrades: Neutral
Price Target: n/a
Current: $33.78
Upside: -
Jul 10, 2019
Assumes: Neutral
Price Target: n/a
Current: $18.34
Upside: -
Aug 15, 2018
Assumes: Outperform
Price Target: $15
Current: $7.39
Upside: +102.98%
Jul 27, 2018
Maintains: Neutral
Price Target: $58 → $61
Current: $44.12
Upside: +38.26%
Jan 17, 2018
Initiates: Outperform
Price Target: $103
Current: $2.65
Upside: +3,786.79%